



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/827,213	04/19/2004	Nicola Lucia Pohl	P06218US01	2894
22885 7	7590 . 10/28/2005		EXAMINER	
•	ORHEES & SEASE,	FERNANDEZ, SUSAN EMILY		
801 GRAND AVENUE SUITE 3200 DES MOINES, IA 50309-2721			ART UNIT	PAPER NUMBER
			1651	

DATE MAILED: 10/28/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)				
Office Action Summary		10/827,213	POHL ET AL.				
		Examiner	Art Unit				
		Susan E. Fernande	z 1651				
Period fo	The MAILING DATE of this communication a or Reply	appears on the cover si	neet with the correspondence a	ddress			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REF CHEVER IS LONGER, FROM THE MAILING nsions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. o period for reply is specified above, the maximum statutory perior tre to reply within the set or extended period for reply will, by stat reply received by the Office later than three months after the ma ed patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COM 1.136(a). In no event, however od will apply and will expire SIX tute, cause the application to be	MUNICATION.  , may a reply be timely filed  (6) MONTHS from the mailing date of this ocome ABANDONED (35 U.S.C. § 133).	,			
Status							
1)	Responsive to communication(s) filed on		•				
· —	• • • • • • • • • • • • • • • • • • • •	——· his action is non-final.					
3)	, <del></del>						
٠,	closed in accordance with the practice unde	•	• •				
Dispositi	ion of Claims						
·		nn					
•	4) Claim(s) 1-28 is/are pending in the application.						
	<ul><li>4a) Of the above claim(s) is/are withdrawn from consideration.</li><li>5) ☐ Claim(s) is/are allowed.</li></ul>						
	6) Claim(s) is/are rejected.						
	Claim(s) is/are objected to.						
· · · · · · · · · · · · · · · · · · ·	Claim(s) <u>1-28</u> are subject to restriction and/o	or election requiremen	•				
	•	or creation requirement	·	,			
Applicati	on Papers						
9)☐ The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
	Applicant may not request that any objection to the	ne drawing(s) be held in	abeyance. See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority ι	under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> </ul>							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
* 5	See the attached detailed Office action for a li	st of the centiled copi	es not received.				
Attachmen	t(s)		·				
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)							
3) 🔲 Infor	e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 r No(s)/Mail Date	per No(s)/Mail Date tice of Informal Patent Application (PT ner:	O-152)				

## **DETAILED ACTION**

Claims 1-28 are pending.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-8 and 22-24, drawn to a C-glycoside analog of isopropyl-β-D-thiogalactopyranoside (IPTG), classified in class 536, subclass 4.1.
- II. Claims 9-15 and 19-21, drawn to a method of inducing protein expression, classified in class 435, subclass 252.33.
- III. Claim 16, drawn to a method of synthesizing a C-glycoside of IPTG comprising treating galactose pentaacetate with methallyltrimethylsilane in the presence of boron trifluoride etherate, classified in class 536, subclass 4.1.
- IV. Claims 17 and 18, drawn to a method of synthesizing a C-glycoside of IPTG comprising treating a haloacetogalactose with an excess of an organomagnesium halide, classified in class 536, subclass 4.1.
- V. Claim 25, drawn to a caged compound, classified in class 536, subclass 4.1.
- VI. Claim 26, drawn to a caged compound, classified in class 536, subclass 4.1.
- VII. Claim 27, drawn to a caged compound, classified in class 536, subclass 4.1.
- VIII. Claim 28, drawn to a caged compound, classified in class 536, subclass 4.1.

  The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the

Art Unit: 1651

product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, it is known that protein expression can be induced with various compounds, including IPTG.

Inventions III and IV are related to Invention I as processes of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, the product as claimed can be made by another and materially different process. Inventions III and IV are clearly materially different processes (see discussion below), thus there are at least ways of making the product.

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different products, restriction is deemed to be proper because these products constitute patentably distinct inventions for the following reasons. Groups I and V-VIII are directed to products that are distinct both physically and functionally, are not required one for the other, and are therefore patentably distinct. The products differ in that they are physically different. Therefore, a search and examination of all products in one patent application would result in an undue burden, since the searches for the five products are not co-extensive, the classification is different, and the subject matter is divergent.

Art Unit: 1651

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Groups II-IV are directed to methods that are distinct both physically and functionally, and are not required one for the other. Specifically, the method of Group II results in the induction of protein expression and requires the use of C-glycoside of IPTG, whereas the methods of Groups III and IV result in the synthesis of C-glycoside of IPTG, and require different components. Groups III and IV differ from each other in that different compounds are used in order to obtain the end-product of C-glycoside of IPTG. Therefore, a search and examination of all three methods in one patent application would result in an undue burden, since the searches for the methods are not co-extensive, the classification is different, and the subject matter is divergent.

The products of Inventions V-VIII are separate and distinct from the methods of Inventions II-IV, wherein the caged compounds of Inventions V-VIII may neither be made by nor used in the methods of Inventions II-IV, and wherein each does not require the other.

Accordingly, restriction is proper.

Because these inventions are distinct for the reason given above and have acquired a separate status in the art because of their recognized divergent subject matter and different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of M.P.E.P. § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 C.F.R. 1.116; amendments submitted after allowance are governed by 37 C.F.R. 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 C.F.R. 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35U.S.C. §§101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained.

Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to maintain the right to rejoinder in accordance with the above policy, Applicant is advised

Art Unit: 1651

that the process claims should be amended during prosecution either to maintain dependency on

the product claims or to otherwise include the limitations of the product claims. Failure to do so

may result in a loss of the right to rejoinder.

Further, note that the protection against double patenting rejections of 35 U.S.C. 121 does

not apply where the restriction requirement is withdrawn by the examiner before the patent

issues. See M.P.E.P. § 804.01.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Susan E. Fernandez whose telephone number is (571) 272-3444.

The examiner can normally be reached on Mon-Fri 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Mike Wityshyn can be reached on (571) 272-0926. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Susan E. Fernandez Assistant Examiner

Art Unit 1651

sef

FRANCISCO PRATS